Data investigation
The Cost-Effectiveness Case, and What Is Inside It
A model projects tirzepatide saving $41,688 per patient and adding half a quality-adjusted life year. Nobody measured that. It was computed, and the adherence assumption is doing most of the work.
A cost-effectiveness analysis reports that tirzepatide saves $41,688 per patient and adds half a quality-adjusted life year compared with semaglutide. It takes the head-to-head SURMOUNT-5 trial and projects it over a lifetime.[1] Nobody measured that figure. It was computed from assumptions, and one of those assumptions does most of the work.
What a cost-effectiveness model does
It takes efficacy from clinical trials, assumes a level of adherence, projects the consequences across years or decades, attaches costs to each event avoided, and discounts it all back to a present value. The output is a single number that looks like a measurement but is a simulation.
That is a legitimate and necessary exercise, because payers have to decide something and waiting decades for outcome data is not an option; two public payers in North Carolina have reached opposite decisions on the same drugs. It also means the result is only as good as its inputs, and the inputs are choices. Even the unit of benefit, the quality-adjusted life year, is a modeled quantity that nobody has ever observed. The same is true of the projected 22% cut in heart risk for people without cardiovascular disease: nobody in that study took the drug.
Nobody measured the $41,688 saving. It was projected over a lifetime from one head-to-head trial.
The assumption that undoes it
Models like this are fed trial efficacy. Outside a trial, these drugs achieve 5.4% to 9.1% weight loss at one year, against the 14.9% and 20.9% their pivotal trials reported (see what these drugs do outside a trial).
The reasons are in many people never reach the dose. Only 58% of people reach maintenance dosing after four weeks, 21% are still on the starting dose, and discontinuation runs from 37% to 56% depending on the drug.
A model that assumes trial adherence computes savings that ordinary care does not generate. The events avoided are avoided in the simulation because the simulated patients kept taking the drug at the studied dose. Four in ten or more of real ones do not.
What is inside the total
The analysis includes reductions in absenteeism (days lost from work) and presenteeism (being at work while unwell and less productive).[1] Both are legitimate societal costs and neither appears on a payer’s balance sheet.
That matters for how the figure is used. From a societal perspective, productivity losses are real money. From an insurer’s perspective, they are somebody else’s money, and an analysis that includes them will always look more favorable than the one a payer runs. Whenever you see a savings figure, first establish whose perspective it was computed from. We apply that test to ten published models in our cost-effectiveness reading list.
How to read any of these
- Whose costs? Societal analyses include productivity; payer analyses do not.
- What adherence was assumed? Trial adherence produces trial savings.
- Over what horizon? Lifetime models bank decades of avoided events from a year or two of data.
- Who funded it? Economic models are commissioned, and the commissioning party chooses the comparator. Three of this model's nine authors, the first among them, list Eli Lilly, the maker of tirzepatide, as their affiliation.[1]
- Does it beat doing nothing, or beat the alternative? Those are different claims and get conflated.
None of this means tirzepatide is not more cost-effective than semaglutide. It may well be, since it produces more weight loss in trials and in ordinary care, and that is the substance underneath the model. The specific dollar figure, though, is a projection with a large adherence assumption inside it, and should be quoted as one.
Frequently Asked Questions
References
- 1.Johansson E, Wilding JPH, Upadhyay N, et al. Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US Journal of Medical Economics. 2026. PMID: 42012820.
Compare the sellers
Related research
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.
6 min read
What These Drugs Do Outside a Trial
Across 44,025 people: semaglutide produced 5.4% weight loss at one year, tirzepatide 9.1%. The pivotal trials reported 14.9% and 20.9%. Continuous therapy recovers about a fifth of the gap.
6 min read
Who Responds in the Real World
Tirzepatide nearly doubled the share reaching 15% weight loss in a year. The same study found outcomes differing by race, where 64 randomized trials found none. The disagreement is the finding.
6 min read
Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison
A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.
6 min read
Beyond BMI: Who Actually Needs Treatment
Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups, so treating by risk costs nothing in weight lost.
6 min read
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
5 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $209/mo
Get started →Embody
From $129/mo
Get started →Collective
From $69/mo + membership
Get started →